Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis

• Published in: Helicobacter (Cambridge, Mass.) Vol. 29; no. 1; pp. e13039 - n/a
• Main Authors: Du, Ren‐Chun, Hu, Yu‐Xin, Ouyang, Yaobin, Ling, Li‐Xiang, Xu, Jing‐Yuan, Sa, Rina, Liu, Xiao‐Shun, Hong, Jun‐Bo, Zhu, Yin, Lu, Nong‐Hua, Hu, Yi
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.01.2024
• Subjects: Adverse events; Amoxicillin; Anti-Bacterial Agents - therapeutic use; Antibiotics; Bismuth; Chi-square test; Clinical trials; Compliance; Drug Therapy, Combination; dual therapy; Effectiveness; Eradication; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Meta-analysis; Penicillin; Proton Pump Inhibitors; Subgroups; Systematic review; Therapy; Treatment Outcome; vonoprazan; amoxicillin; Helicobacter pylori; vonoprazan; eradication; dual therapy

Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin (VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different regions with inconsistent results reported. In this systematic review and meta‐analysis, we aimed to evaluate the effic...